Partenaires

CNRS
Logo Université de Strasbourg
Logo IREBS



Rechercher

Sur ce site

Sur le Web du CNRS


Accueil > Drug Discovey Center > Drug technologies

Drug technologies

The Drug Discovery TechMedILL platform has the expertise and high technology equipment for the rapid assessment of ADME / Tox properties. It is operated by the Integrative Biological Chemistry platform (PCBIS), a joint facility unit of the CNRS and the University of Strasbourg in Strasbourg - Illkirch (UMS 3286).

The platform offers TechMedILL services in ADME / Tox aimed at academic laboratories but also to private companies. The proposed analyses are conducted using reliable standardized methods with short delays.

The TechMedILL platform is located in the premises of ESBS (School of Biotechnology of Strasbourg). It is implemented by the Integrative Biological Chemistry platform (PCBIS), a joint facility unit of the CNRS and the University of Strasbourg in Illkirch (UMS 3286).

 

Presentation of the platform

The search for new molecules with therapeutic potential is a challenge for researchers of the 21st century. The production and identification of potentially-therapeutic molecules is nowadays easier, thanks to new technologies such as combinatorial chemistry and high throughput screening.

Large numbers of hits are obtained during high throughput screenings, but only a few will eventually meet the drug market. All the other hits will be rejected during their development. Such a large large number of "positive hits" actually generates new problems due to limited capabilities to optimize high throughput chemical screening and to monitor the pharmacological outcome of these molecules in animal models.

The analysis, at an early stage, of the biological effects of molecules in living organisms is becoming more crucial. Therefore, the study of molecular properties such as solubility, absorption, distribution, metabolism, elimination (ADME) and toxicity should be undertaken as soon as possible when developing new molecules. Such an analysis requires techniques relevant to analytical sciences, in vitro assays or even in silico studies to obtain data that predict the in vivo behavior of molecules.

The «Preclinical drug technology» hosted at Irebs/ESBS offers expertise focused on preclinical development and drug formulation. This advanced research know-how facilitates the transfer of drug candidates into clinical development and administration to man.

Our expertise, services and advisory activities provide a real impact on the optimal development of molecules known that will go through the constraints of their chemical optimization.

- For more information, please visit the Drug Discovery Center website.

Contact :

Pascal VILLA
UMS 3286 (PCBIS)
ESBS - Boulevard Sébastien Brant
67401 ILLKIRCH Cedex
- Office: (33) (0) 3 68 85 48 71
- Lab: (33) (0) 3 68 85 48 70
- Fax: (33) (0) 3 68 85 44 15